The FDA granted orphan-drug status to Telik's Telintra, or ezatiostat HCL, an experimental drug for myelodysplastic syndrome. In studies, Telintra was associated with multilineage response and the need for fewer red blood cell transfusions among MDS patients.
Telik's MDS candidate Telintra wins orphan-drug designation
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||